Plus Therapeutics Stock Market Value
| PSTV Stock | USD 1.28 0.02 1.59% |
| Symbol | Plus |
Plus Therapeutics Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Plus Therapeutics. If investors know Plus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Plus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.37) | Revenue Per Share 1.188 | Quarterly Revenue Growth (0.31) | Return On Assets (0.69) | Return On Equity (5.22) |
The market value of Plus Therapeutics is measured differently than its book value, which is the value of Plus that is recorded on the company's balance sheet. Investors also form their own opinion of Plus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Plus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Plus Therapeutics' market value can be influenced by many factors that don't directly affect Plus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Plus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Plus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Plus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Plus Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Plus Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Plus Therapeutics.
| 11/01/2024 |
| 12/01/2024 |
If you would invest 0.00 in Plus Therapeutics on November 1, 2024 and sell it all today you would earn a total of 0.00 from holding Plus Therapeutics or generate 0.0% return on investment in Plus Therapeutics over 30 days. Plus Therapeutics is related to or competes with Tff Pharmaceuticals, Eliem Therapeutics, Inhibrx, and Enliven Therapeutics. Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercia... More
Plus Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Plus Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Plus Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.02) | |||
| Maximum Drawdown | 41.21 | |||
| Value At Risk | (9.56) | |||
| Potential Upside | 7.63 |
Plus Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Plus Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Plus Therapeutics' standard deviation. In reality, there are many statistical measures that can use Plus Therapeutics historical prices to predict the future Plus Therapeutics' volatility.| Risk Adjusted Performance | 0.0081 | |||
| Jensen Alpha | (0.02) | |||
| Total Risk Alpha | (0.97) | |||
| Treynor Ratio | (0.18) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Plus Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Plus Therapeutics Backtested Returns
Plus Therapeutics maintains Sharpe Ratio (i.e., Efficiency) of -0.016, which implies the firm had a -0.016% return per unit of risk over the last 3 months. Plus Therapeutics exposes twenty-four different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check Plus Therapeutics' Variance of 32.48, risk adjusted performance of 0.0081, and Coefficient Of Variation of (132,798) to confirm the risk estimate we provide. The company holds a Beta of 0.0784, which implies not very significant fluctuations relative to the market. As returns on the market increase, Plus Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Plus Therapeutics is expected to be smaller as well. At this point, Plus Therapeutics has a negative expected return of -0.0919%. Please make sure to check Plus Therapeutics' value at risk, rate of daily change, as well as the relationship between the Rate Of Daily Change and relative strength index , to decide if Plus Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.69 |
Very good reverse predictability
Plus Therapeutics has very good reverse predictability. Overlapping area represents the amount of predictability between Plus Therapeutics time series from 1st of November 2024 to 16th of November 2024 and 16th of November 2024 to 1st of December 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Plus Therapeutics price movement. The serial correlation of -0.69 indicates that around 69.0% of current Plus Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.69 | |
| Spearman Rank Test | -0.26 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Plus Therapeutics lagged returns against current returns
Autocorrelation, which is Plus Therapeutics stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Plus Therapeutics' stock expected returns. We can calculate the autocorrelation of Plus Therapeutics returns to help us make a trade decision. For example, suppose you find that Plus Therapeutics has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Plus Therapeutics regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Plus Therapeutics stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Plus Therapeutics stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Plus Therapeutics stock over time.
Current vs Lagged Prices |
| Timeline |
Plus Therapeutics Lagged Returns
When evaluating Plus Therapeutics' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Plus Therapeutics stock have on its future price. Plus Therapeutics autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Plus Therapeutics autocorrelation shows the relationship between Plus Therapeutics stock current value and its past values and can show if there is a momentum factor associated with investing in Plus Therapeutics.
Regressed Prices |
| Timeline |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Plus Stock Analysis
When running Plus Therapeutics' price analysis, check to measure Plus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Plus Therapeutics is operating at the current time. Most of Plus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Plus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Plus Therapeutics' price. Additionally, you may evaluate how the addition of Plus Therapeutics to your portfolios can decrease your overall portfolio volatility.